Nyxoah SA (NYXH)
Nyxoah makes the Genio system, an implant that treats obstructive sleep apnea by stimulating the hypoglossal nerve. It last closed at $0.88 on Nov 17, down 1.10% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From NYXH's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 26). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on NYXH in the past 90 days. The average target is $3.00, with a high of $3.00 and a low of $3.00, compared with the last close of $0.88.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 27 | Cantor Fitzgerald | Target lowered | Buy | $6 → $3 |
| Aug 17 | Cantor Fitzgerald | Maintained | Buy | $6 |
| Aug 6 | Piper Sandler | Reiterated | Buy | $6 |
| Jun 17 | Stifel | Target lowered | Hold | $5 → $3 |
| May 12 | Stifel | Downgrade | Hold | $5 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 156% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 37), near oversold. The nearest support is the 20 day average at $0.88, and the nearest resistance the Pivot at $0.89.
| RSI (14) | 37.37 | Weak, oversold below 30 | Neutral |
| MACD | -0.08 | Above its signal line | Bullish |
| Stochastic | 58.4 | Middle of its range | Neutral |
| ADX (14) | 30.7 | Trending down | |
| Williams %R | -35.7 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 20.7 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −1.5% | Change over 10 sessions | Bearish |
| ATR (14) | $0.05 | Typical daily range, 5.9% of price |
| RSI (14) | 26.58 | Oversold below 30 | Oversold |
| MACD | -0.49 | Above its signal line | Bullish |
| Stochastic | 7.4 | Near the bottom of its range | Oversold |
| ADX (14) | 35.1 | Trending down | |
| Williams %R | -91.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -122.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −42.6% | Change over 10 sessions | Bearish |
| ATR (14) | $0.26 | Typical daily range, 29.1% of price |
What happened before
See how NYXH did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NYXH has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in NYXH in the last 90 days.
NYXH Institutional Ownership
Full report →- ●20 buying vs 18 selling
- ▼Shares held by funds -11.7%
- ▼Funds holding -8
- ▼Superinvestors: 1 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 37 | 45 | −17.8% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | – | – | – |
| New / increased | 7 / 13 | 19 / 6 | −20.0% |
| Reduced / sold out | 5 / 13 | 3 / 8 | +63.6% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NYXH is in one of them and how their past NYXH trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NYXH in an article yet. Here's the latest on the wider market.
About Nyxoah SA
Nyxoah develops and sells the Genio system, a medical device for treating obstructive sleep apnea, a condition in which the airway repeatedly becomes blocked during sleep. The Genio system is an implant placed through a single incision under the chin that provides bilateral stimulation of the hypoglossal nerve to help keep the airway open. It is intended for adults with moderate to severe sleep apnea who cannot tolerate or adhere to CPAP, the standard mask-based therapy. The company sells to hospitals and sleep physicians in Europe and the United States and is based in Mont-Saint-Guibert.
- Headquarters
- Mont-Saint-Guibert


